J. Buciak

Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein.

W. Pardridge, J. Buciak, J. Yang, 1998, The Journal of pharmacology and experimental therapeutics.

Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector.

W. Pardridge, J. Buciak, Jing Yang, 1990, The Journal of pharmacology and experimental therapeutics.

Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein.

W. Pardridge, Jing Yang, J. Buciak, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Human brain microvascular DR‐antigen

W. Tourtellotte, W. Pardridge, J. Buciak, 1989, Journal of neuroscience research.

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

W. Pardridge, J. Buciak, Jing Yang, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody.

U. Bickel, W. Pardridge, J. Buciak, 1994, Immunology letters.

Enhanced endocytosis and anti-human immunodeficiency virus type 1 activity of anti-rev antibodies after cationization.

U. Bickel, W. Pardridge, J. Buciak, 1994, The Journal of infectious diseases.

Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins.

W. Pardridge, J. Buciak, J. Yang, 1994, The Journal of infectious diseases.